A collaborative effort between investigators at Roswell Park Comprehensive Cancer Center and the Center for Molecular Immunology in Havana, Cuba, has revealed a new strategy for correcting immune dysfunction in cancer patients.
People with metastatic kidney cancer who orally took a live biotherapeutic product called CBM588 while in treatment with immunotherapy and enzymatic tyrosine kinase inhibitors experienced improved health outcomes, according to research from City of Hope.
